In the latest trading session, 0.48 million Corvus Pharmaceuticals Inc (NASDAQ:CRVS) shares changed hands as the company’s beta touched 1.14. With the company’s most recent per share price at $7.70 changing hands around $0.14 or 1.85% at last look, the market valuation stands at $481.64M. CRVS’s current price is a discount, trading about -0.26% off its 52-week high of $7.72. The share price had its 52-week low at $1.05, which suggests the last value was 86.36% up since then. When we look at Corvus Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.74 million shares, with the 3-month average coming to 475.42K.
Analysts gave the Corvus Pharmaceuticals Inc (CRVS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRVS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Corvus Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.1.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information
Instantly CRVS is in green as seen in intraday trades today. With action 14.58%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 337.51%, with the 5-day performance at 14.58% in the green. However, in the 30-day time frame, Corvus Pharmaceuticals Inc (NASDAQ:CRVS) is 41.55% up. Looking at the short shares, we see there were 2.15 million shares sold at short interest cover period of 4.15 days.
The consensus price target for the stock as assigned by Wall Street analysts is 9.5, meaning bulls need an upside of 18.95% from its recent market value. According to analyst projections, CRVS’s forecast low is 7 with 12 as the target high. To hit the forecast high, the stock’s price needs a -55.84% plunge from its current level, while the stock would need to tank 9.09% for it to hit the projected low.
Corvus Pharmaceuticals Inc (CRVS) estimates and forecasts
Data shows that the Corvus Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 403.27% over the past 6 months, a 19.64% in annual growth rate that is considerably higher than the industry average of 17.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.89%. The 2024 estimates are for Corvus Pharmaceuticals Inc earnings to increase by 25.45%.
CRVS Dividends
Corvus Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2024-Nov-05.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.02% of Corvus Pharmaceuticals Inc shares while 44.19% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 46.04%. There are 44.19% institutions holding the Corvus Pharmaceuticals Inc stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 14.1596% of the shares, roughly 6.94 million CRVS shares worth $12.64 million.
SAMLYN CAPITAL, LLC holds the second largest percentage of outstanding shares, with 12.4861% or 6.12 million shares worth $11.14 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 1.16 shares estimated at $9.14 million under it, the former controlled 1.85% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.69% of the shares, roughly 429.52 shares worth around $3.39 million.
